Aptevo Therapeutics Inc. — Form S-1
Filed August 21, 2026 · analyzed by the Registration Agent
S-1
▼ Likely negative
significance 78/100
What the filing says
On August 12, 2026, Aptevo Therapeutics (market cap ~$9.8M) completed a private placement issuing 861,708 Pre-Funded Warrants and 4,308,540 Common Warrants (exercise price $4.03/share) plus 1,274,610 Inducement Warrants to three funds (Armistice, Hudson Bay, Sabby). The company received ~$4.5M gross proceeds. The transaction also induced exercise of 254,922 existing warrants at the reduced $4.03 price. Total resale shares registered: 6,444,858 (355% of current outstanding 1.81M shares). No proceeds flow to company from resales; all go to selling stockholders. Stock price on August 20, 2026 was $2.76/share, down 65% from year-ago levels.
Why this rating
Massive dilution (6.4M new shares vs. 1.8M outstanding) threatens equity base. $4.5M capital infusion is material (46% of market cap) but heavily offset by warrant overhang, delisting risk warnings, and going-concern uncertainty noted in audit.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.